A Phase 2 interventional study of Lunsekimig and Short-Acting Beta Agonists (SABA) in Asthma, sponsored by Sanofi. Active, not recruiting at 221 sites in 22 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.
Among the 37 studies in Asthma by Sanofi, this one is the 13th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 2, and was the 36th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Canada, France and 3 more countries
Ages 6+
Sanofi · Sites in United States, Argentina, Brazil and 17 more countries
Ages 18+
Sanofi · Sites in United States, Argentina, Brazil and 13 more countries
Ages 2–5
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 556 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 450 across the 31 interventional studies, 144 across the 5 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Asthma by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06676319SanofiStudy of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Asthma by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lunsekimig (SC injection) every 4 weeks
Drug: Lunsekimig · Drug: Short-Acting Beta Agonists (SABA) · Drug: Fluticasone/Salmeterol · Drug: Budesonide/Formoterol · Drug: Budesonide/Albuterol
Participants will receive placebo (SC injection) every 4 weeks
Drug: Short-Acting Beta Agonists (SABA) · Drug: Placebo · Drug: Fluticasone/Salmeterol · Drug: Budesonide/Formoterol · Drug: Budesonide/Albuterol
Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection
Also known as: SAR443765
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation
Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection
Drug pages: Fluticasone · Salmeterol Xinafoate
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration:Oral Inhalation
Drug pages: Budesonide · Formoterol
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation
Drug pages: Budesonide · Albuterol
Pharmaceutical form: Aerosol for inhalation; Route of administration: Oral Inhalation
Annualized rate of asthma exacerbation events
Asthma exacerbation event defined as: worsening of asthma requiring the use of systemic corticosteroids for ≥3 days; or hospitalization or emergency room visit due to asthma and requiring the use of systemic corticosteroids or death due to asthma
Time frame: From baseline up to 52 weeks
Change from baseline in prebronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Time frame: From baseline to week 52
Change from baseline in Asthma Control Questionnaire5 (ACQ-5) score
The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.
Time frame: From baseline to week 52
Change from baseline in FeNO level
Time frame: From baseline to week 52
Annualized rate of loss of asthma control events (LOAC) events
Annualized rate of LOAC events defined by 1 or more of the following criteria: * ≥30% reduction from baseline in morning PEF on 2 consecutive days * ≥6 additional reliever puffs of SABA in a 24-hour period (compared to baseline) on 2 consecutive days OR ≥4 additional puffs of low-dose budesonide/formoterol or budesonide/albuterol in a 24-hour period (compared to baseline) on 2 consecutive days * Worsening of asthma requiring the use of systemic corticosteroids for ≥3 days * Hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids (asthma exacerbation event) * Death due to asthma
Time frame: From baseline to week 52
Annualized rate of asthma exacerbations requiring hospitalization or emergency room or urgent care visit
Time frame: From baseline to week 52
Total systemic corticosteroid dose exposure
Time frame: From baseline to week 52
Change from baseline in Asthma Quality of Life Questionnaire Standardized (AQLQ{S}) scores
Time frame: From baseline to week 52
Change from baseline in the Asthma Daytime Symptom Diary (ADSD) daily morning and evening score
Time frame: From baseline to week 52
Serum lunsekimig concentrations
Time frame: From baseline to week 56
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Time frame: From baseline to week 56
Incidence of participants with treatment-emergent adverse events (TEAEs), including local reactions, adverse events of special interests (AESIs), serious adverse events (SAEs)
Time frame: From baseline to week 56
Showing the first 100 of 221 sites across 22 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 31 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lunsekimig